Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA , and AKT1
2009
TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
2014
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
2015 StandoutNobel
Nucleic acid detection with CRISPR-Cas13a/C2c2
2017 StandoutScience
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
2009 Science
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
2010
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
2010
Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations
2009
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
2010
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
2010 StandoutNobel
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
2010
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
2016
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
Cell-free circulating tumor DNA in cancer
2016
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
ErbB receptors and signaling pathways in cancer
2009
Cancer Cell Metabolism
2011
Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma
2012
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
2016
IDH1andIDH2Mutations in Gliomas
2009 Standout
MYC on the Path to Cancer
2012 Standout
Neat1 is a p53-inducible lincRNA essential for transformation suppression
2017
A view on drug resistance in cancer
2019 StandoutNature
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
2010
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
2011
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
2010
Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ
2013 Standout
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
2009 Standout
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
2009
The biology and management of non-small cell lung cancer
2018 StandoutNature
Integrating liquid biopsies into the management of cancer
2017
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
IDH mutations in glioma and acute myeloid leukemia
2010
RAS oncogenes: weaving a tumorigenic web
2011
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
2012 StandoutNatureNobel
Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
2014
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
2013
Relationship between Tumor Enhancement, Edema,IDH1Mutational Status,MGMTPromoter Methylation, and Survival in Glioblastoma
2012
Functional Classification and Experimental Dissection of Long Noncoding RNAs
2018 Standout
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
2014 StandoutNature
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation
2012
Monoclonal antibody specific for IDH1 R132H mutation
2009
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
2009 StandoutNature
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
2015 Standout
Mitochondria: In Sickness and in Health
2012 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
2015 StandoutNobel
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Dynamic RNA Modifications in Gene Expression Regulation
2017 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Genetic Alterations Associated With Progression From Pancreatic Intraepithelial Neoplasia to Invasive Pancreatic Tumor
2013
Regulation of cancer cell metabolism
2011 Standout
Dendritic cells in cancer immunotherapy
2010
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
2019
Malignant Gliomas in Adults
2008 Standout
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
2015
IDH1 mutation of gliomas with long-term survival analysis
2012
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
EMT: 2016
2016 Standout
Oxidative Stress in Cancer
2020 Standout
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
2015
Cancer immunotherapy comes of age
2011 StandoutNature
Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells
2012
TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1
2011
PI3K/Akt: getting it right matters
2008
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
2013 Standout
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
2009
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
AKT/PKB Signaling: Navigating the Network
2017 Standout
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
2010
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas
2013
Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production
2011
AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
2016
Drugging the undruggable RAS: Mission Possible?
2014
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Mutations in GNA11 in Uveal Melanoma
2010 Standout
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
2011
Histone lysine methylation and demethylation pathways in cancer
2010
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
2010
IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication
2010
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Clues from cell metabolism
2010 StandoutNatureNobel
Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
2012
Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism
2010
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis
2012
A Comprehensive Survey of Ras Mutations in Cancer
2012 Standout
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
2010
Metabolic reprogramming and cancer progression
2020 StandoutScience
Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas
2009
Cancer Genome Landscapes
2013 StandoutScience
Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis
2010
Roles for Growth Factors in Cancer Progression
2010
Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
2011
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
2010
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
2012
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Works of Simona Lamba being referenced
Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma
2007
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
2015
Absence of AKT1 Mutations in Glioblastoma
2009
Molecular profiling of the âplexinomeâ in melanoma and pancreatic cancer
2009
Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes
2008
RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
2014
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
2010
IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors
2009
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
2009
Mutational Profile of GNAQQ209 in Human Tumors
2009
AKT1E17K in human solid tumours
2008
The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma
2010
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
2010
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
2014
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
2008
High-dose vitamin C enhances cancer immunotherapy
2020